nach oben

Erschienen in:

01.04.2011 | Original Article

Women’s perspective of botulinum toxin treatment for overactive bladder symptoms

verfasst von: G. Alessandro Digesu, Demetri Panayi, Caroline Hendricken, Michelle Camarata, Ruwan Fernando, Vikram Khullar

Erschienen in: International Urogynecology Journal | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

This study aimed to evaluate the women’s’ views and expectations about outcomes and complications of botulinum toxin treatment for overactive bladder (OAB) symptoms.

Methods

Consecutive women with OAB symptoms and detrusor overactivity were requested to fill out a multiple choice questionnaire to assess whether they would consider botulinum and what outcomes as well as complications they would find acceptable to undergo this treatment.

Results

Two hundred sixty-one women, mean age of 58 (range, 38–78) years, were studied. Two hundred twenty-four were treatment-naive women (group A), while 37 were no responders to anticholinergics (group B). Only 49.6% of women in group A and 54% in group B would accept botulinum toxin. No significant differences were found between treatment-naive women and non-responders to anticholinergics (p > 0.05).

Conclusions

Acceptance of botulinum toxin treatment involves a complex interaction of efficacy and possible complications. The balance of these factors changes the acceptability of the treatment.

Nur mit Berechtigung zugänglich

Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 21:167–178PubMedCrossRef

Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336PubMed

Abrams P (2000) Introduction: overactive bladder and its treatments. Urology 55:1–2CrossRef

Stewart WF, Corey R, Herzog AR et al (2001) Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynaecol J 12:S66

Srikrishna S, Robinson D, Cardozo L, Vella M (2007) Management of overactive bladder syndrome. Postgrad Med J 83(981):481–486PubMedCrossRef

Andersson K-E (1988) Current concepts in the treatment of disorders of micturition. Drugs 35:477–494PubMedCrossRef

Payne CK, Kelleher C (2007) Redefining response in overactive bladder syndrome. BJU Int 99(1):101–106PubMedCrossRef

Salvatore S, Khullar V, Cardozo L et al (2005) Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. Eur J Obstet Gynecol Reprod Biol 119:237–241PubMedCrossRef

Kelleher CJ, Cardozo LD, Khullar V et al (1997) A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104:988–993PubMedCrossRef

10.

Rapp DE, Lucioni A, Katz EE et al (2004) Use of botulinum toxin A for the treatment of refractory overactive bladder symtptoms: an initial experience. Urolog 63:1071–1075CrossRef

11.

Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum A toxin injection in the treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63:868–872PubMedCrossRef

12.

Chancellor MB, O’Leary M, Erickson J (2003) Successful use of bladder botulinum toxin injection to treat refractory overactive bladder. J Urol 169(suppl):351

13.

Abrams P, Andersson KE, Birder L et al (2009) Proceedings of the 4th International consultation on incontinence. Recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. In: Abrams P, Cardozo L, Khouri S, Wein A (eds) Incontinence. Plymouth, UK, pp 1767–1798

14.

Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697PubMedCrossRef

15.

Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB (2004) Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 64:871–875PubMedCrossRef

16.

Apostolidis A, Popat R, Yiangou Y et al (2005) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174:977–982PubMedCrossRef

17.

Schmid DM, Sauermann P, Werner M et al (2006) Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176(1):177–185PubMedCrossRef

18.

Patel AK, Patterson JM, Chapple CR (2006) Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur Urol 50:684–709PubMedCrossRef

19.

Sahai A, Dowson C, Khan MS, Dasgupta P (2008) Re: efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 101(4):515–516PubMedCrossRef

20.

Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R (2007) Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 100(6):1302–1306PubMedCrossRef

21.

Kuo HC (2007) Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 178:1359–1363PubMedCrossRef

22.

Mattiasson A, Djurhuus JC, Fonda D, Lose G, Nordling J, Stohrer M (1998) Standardisation of outcome studies in patients with lower urinary tract dysfunction: a report on general principles from the standardisation committee of the International Continence Society. Neurourol Urodyn 17:249–253PubMedCrossRef

23.

Blaivis JG, Appell RA, Fantl JA et al (1997) Standards of efficacy for evaluation of treatment outcomes in urinary incontinence: recommendations of the urodynamic society. Neurourol Urodyn 16:145–147CrossRef

24.

Blaivas JG (1998) Outcome measures for urinary incontinence. Urology 51:11–19PubMedCrossRef

25.

Scientific Committee of the First Consultation on Incontinence (2000) Assessment and treatment of urinary incontinence. Lancet 355:2153–2158CrossRef

26.

Apostolidis A, Dasgupta P, Denys P et al (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55(1):100–119PubMedCrossRef

Titel: Women’s perspective of botulinum toxin treatment for overactive bladder symptoms
verfasst von: G. Alessandro Digesu
Demetri Panayi
Caroline Hendricken
Michelle Camarata
Ruwan Fernando
Vikram Khullar
Publikationsdatum: 01.04.2011
Verlag: Springer-Verlag
Erschienen in: International Urogynecology Journal / Ausgabe 4/2011
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-010-1315-x

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Welche Übungen helfen gegen Diastase recti abdominis?

30.04.2024 Schwangerenvorsorge Nachrichten

Die Autorinnen und Autoren einer aktuellen Studie aus Griechenland sind sich einig, dass Bewegungstherapie, einschließlich Übungen zur Stärkung der Bauchmuskulatur und zur Stabilisierung des Rumpfes, eine Diastase recti abdominis postpartum wirksam reduzieren kann. Doch vieles ist noch nicht eindeutig belegt.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2011

Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis

Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome

Postoperative catheterization after anterior colporrhaphy: 2 versus 5 days. A multicentre randomized controlled trial

Nerve injury locations during retropubic sling procedures

Myofascial pain and pelvic floor dysfunction in patients with interstitial cystitis